Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedOct 30, 2024Phenylephrine HCl 0.9% Sodium Chloride Injection USPcGMP violationsFresenius Kabi Compounding, LLC · D-0016-2025Class IITerminatedOct 30, 2024Phenylephrine HCl 0.9% Sodium Chloride Injection USPcGMP violationsFresenius Kabi Compounding, LLC · D-0015-2025Class IITerminatedOct 30, 2024Phenylephrine HCl 0.9% Sodium Chloride Injection USPCGMP violationsFresenius Kabi Compounding, LLC · D-0014-2025Class IIOngoingOct 23, 2024First Aid Antiseptic OintmentIncorrect/Undeclared Excipients: The inactive ingredients labeled on the product boxes and tubes are listed as "mineral oil , petrolatum ". The inactive ingredients in...Zhejiang Jingwei Pharmaceutical Co., Ltd. · D-0013-2025Class ITerminatedOct 23, 2024Atovaquone Oral SuspensionMicrobial Contamination of a Non-sterile Product: The product was found to be contaminated with Cohnella bacteria.Bionpharma Inc. · D-0012-2025Class IIOngoingOct 23, 2024Dapsone Gel 7.5%CrystallizationViona Pharmaceuticals Inc · D-0011-2025Class IITerminatedOct 23, 2024Cisplatin InjectionFailed Impurities/Degradation Specifications.Accord Healthcare, Inc. · D-0010-2025Class IICompletedOct 23, 2024Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limitBreckenridge Pharmaceutical, Inc · D-0009-2025Class IOngoingOct 16, 2024Vail-Bon Jie Yang Wan capsulesMarketed without an approved NDA/ANDA: Product found to be tainted with undeclared dexamethasone and chlorpheniramine.123Herbals · D-0008-2025Class IIOngoingOct 9, 2024PluvictoCGMP deviationsAdvanced Accelerator Applications USA, Inc. · D-0007-2025Class IIOngoingOct 9, 2024RyaltrisDefective Delivery System: The dip tube is clogged causing the spray not to work.Glenmark Pharmaceuticals Inc., USA · D-0006-2025Class ITerminatedOct 9, 2024VekluryPresence of Particulate Matter: Presence of glass particle.Gilead Sciences, Inc. · D-0005-2025Class IOngoingOct 9, 2024Gold Hard Steel Plus LiquidMarketed without an approved NDA/ANDA: FDA analysis found products to be tainted with undeclared acetaminophen and sildenafil.Supercore Products Group Inc. · D-0004-2025Class IOngoingOct 9, 2024Hard Steel CapsulesMarketed without an approved NDA/ANDA: FDA analysis found products to be tainted with undeclared acetaminophen and sildenafil.Supercore Products Group Inc. · D-0003-2025Class IIIOngoingOct 9, 2024Ciclopirox Gel 0.77%Defective Container: Firm received complaints of broken tube at the seal.Glenmark Pharmaceuticals Inc., USA · D-0002-2025Class IITerminatedOct 9, 2024Atorvastatin Calcium TabletsPresence of Foreign Tablets/Capsules: A Carbamazepine Extended-Release 400 mg tablet was found in a 1000-count bottle of Atorvastatin Calcium Tablets, USP 40 mg.Nivagen Pharmaceuticals Inc · D-0001-2025Class IIOngoingOct 2, 2024Mycophenolic Acid Delayed-Release Tablets USPFailed Dissolution SpecificationsAscend Laboratories, LLC · D-0668-2024Class IIOngoingOct 2, 2024EnviroClean Hand Sanitizer GelCGMP deviationsEnviroServe Chemicals Inc. · D-0667-2024Class IIOngoingOct 2, 2024Infla-650 Herbal Dietary SupplementMarketed without an approved NDA/ANDA: FDA analysis found product to be tainted with undeclared acetaminophen, diclofenac, and phenylbutazone.Guru Inc. · D-0666-2024Class IIOngoingOct 2, 2024Refresh LACRI-LUBELack of Assurance of Sterility: The impacted lots may contain a breach in the tube seal.AbbVie Inc. · D-0665-2024Class IIOngoingOct 2, 2024Refresh P.MLack of Assurance of Sterility: The impacted lots may contain a breach in the tube seal.AbbVie Inc. · D-0664-2024Class IITerminatedOct 2, 2024Pyridoxine HCLLack of Assurance of SterilityEmpower Pharmacy · D-0663-2024Class IIOngoingOct 2, 2024Vivier Sheer SPF 30 Mineral With AntioxidantsMicrobial Contamination of Non-Sterile ProductVivier Pharma, Inc. · D-0662-2024Class IITerminatedOct 2, 2024Proparacaine Hydrochloride Ophthalmic SolutionTemperature abuse: Products exposed to improper temperature above drug label specifications.Mckesson Medical-Surgical Inc. Corporate Office · D-0661-2024Class IICompletedOct 2, 2024Mupirocin OintmentSubpotent DrugGlenmark Pharmaceuticals Inc., USA · D-0660-2024Class IIIOngoingSep 25, 2024AcetaZOLAMIDE TabletsDiscolorationRubicon Research Private Limited · D-0659-2024Class IIITerminatedSep 18, 2024Just Right 5000LABELING: LABEL MIX-UP.Elevate Oral Care · D-0658-2024Class IIOngoingSep 18, 2024BARRIER THERAPY SKIN PROTECTANT CREAMMicrobial contamination of non-sterile Products -Prequel Skin · D-0657-2024Class IIOngoingSep 11, 2024TIRZEPATIDE 60 mg/3mLLack of Assurance of SterilityProRx LLC · D-0656-2024Class IIOngoingSep 11, 2024TIRZEPATIDE 20 mg/2mLLack of Assurance of SterilityProRx LLC · D-0655-2024Class IIOngoingSep 11, 2024Semaglutide / Cyanocobalamin Injection: 2.5/0.5 mg/mLLack of Assurance of SterilityProRx LLC · D-0654-2024Class IIOngoingSep 11, 2024SEMAGLUTIDE 10mg/4mLLack of Assurance of SterilityProRx LLC · D-0653-2024Class IIOngoingSep 11, 2024SEMAGLUTIDE 5mg/2mLLack of Assurance of SterilityProRx LLC · D-0652-2024Class IIOngoingSep 11, 2024Tirzepatide 2 mLLack of Assurance of SterilityProRx LLC · D-0651-2024Class IIOngoingSep 11, 2024SemaglutideLack of Assurance of SterilityProRx LLC · D-0650-2024Class IOngoingSep 11, 2024HeparinMicrobial Contamination of Sterile Products; out of limit results obtained for endotoxin testing.Baxter Healthcare Corporation · D-0649-2024Class IITerminatedSep 4, 2024Cefixime for Oral Suspension USPSubpotent Drug- An out of specification ( OOS ) result observed in assay test during 18-month long term stability study.Lupin Pharmaceuticals Inc. · D-0648-2024Class IIOngoingSep 4, 2024Ibuprofen TabletsFailed Impurities/Degradation Specifications - at 18-month Stability testingPreferred Pharmaceuticals, Inc. · D-0647-2024Class IIOngoingSep 4, 2024IBU Ibuprofen TabletsFailed impurities/degradation specifications: results for unknown impurity, were 0.13% and 0.11% respectively, exceeding the 0.10% specification limit.Dr. Reddy's Laboratories, Inc. · D-0646-2024Class IIOngoingSep 4, 2024IBU Ibuprofen TabletsFailed impurities/degradation specifications: results for unknown impurity, were 0.13% and 0.11% respectively, exceeding the 0.10% specification limit.Dr. Reddy's Laboratories, Inc. · D-0645-2024